PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 455
- Registration Number
- NCT04230213
- Locations
- 🇺🇸
Graves Gilbert Clinic, Bowling Green, Kentucky, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Metroplex Clinical Research Center, Dallas, Texas, United States
Acute Myeloid Leukemia Real World Treatment Patterns
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04230564
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
- Conditions
- Lower Resp Tract InfectionRespiratory Syncytial Virus (RSV)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51
- Registration Number
- NCT04225897
- Locations
- 🇦🇷
Hospital Interzonal General de Agudos "Dr. José Penna", Bahia Blanca, Buenos Aires, Argentina
🇦🇷Hospital Italiano Regional Del Sur, Bahia Blanca, Buenos Aires, Argentina
🇦🇷Hospital General de Ninos Pedro de Elizalde, Ciudad Autonoma de Buenos Aires, Caba, Argentina
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 236
- Registration Number
- NCT04218084
- Locations
- 🇪🇬
Ain Shams University Hospital-Clinical Research Center (MASRI), Cairo, Egypt
🇬🇭Department of Child Health, University of Ghana Medical School, College of Health Sciences, Accra, Ghana
🇮🇹Azienda Ospedaliera Universitaria (AOU) Meyer, Firenze, Italy
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: PF-06826647 300 mg QDDrug: PlaceboDrug: PF-06826647 100 mg QDDrug: PF-06826647 600 mg QDDrug: PF-6826647 400 mg QD
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04209556
- Locations
- 🇺🇸
Hope Clinical Research, Canoga Park, California, United States
🇺🇸ADVA Clinical Research, Inglewood, California, United States
🇺🇸Centinela Valley Endoscopy Center, Inglewood, California, United States
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
- Conditions
- Community Acquired PneumoniaComplicated Skin and Soft Tissue Infection
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 317
- Registration Number
- NCT04198571
- Locations
- 🇧🇷
Real Hospital Português de Beneficência, Recife, PE, Brazil
🇧🇷Hospital Esperança, Recife, Brazil
🇨🇴Clínica Las Américas, Medellin, Antioquia, Colombia
The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04198844
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
- Conditions
- Hepatic ImpairmentHealthy Participants
- Interventions
- Drug: PF-06835919 25 mg
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT04193436
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
🇨🇿Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
🇸🇰Summit Clinical Research, s.r.o.,, Bratislava, Slovakia
Open-Label Extension of Voxelotor
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT04188509
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Healthcare of Atlanta Scottish Rite, Atlanta, Georgia, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Safety and Efficacy of Trastuzumab BS
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT04181333
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan